News

04 December 2017 - Poster presentations at ACNP and BPS meetings

Preclinical data on Neurolixis projects will be presented at this month's ACNP (American College of Neuropsychopharmacology) and BPS (British Pharmacological Society) meetings. At ACNP, Prof. Luc Zimmer will report brain imaging data on the Neurolixis 'biased agonists', NLX-112 and NLX-101, showing that they differentially target-HT1A receptors in specific brain regions. At BPS, Dr. Ana Abdala Sheikh, will describe results from transgenic Rett syndrome mice showing their breathing deficits are diminished when treated with NLX-101. Overall, the observations support Neurolixis' CNS drug development programs: NLX-112 for dyskinesia in Parkinson's disease and NLX-101 for respiratory dysfunction.

Simultaneous PET/MR Imaging for the Exploration of Serotonin 5-HT1A Receptor Biased Agonists
Vidal B, Fieux S, Redouté J, Le Bars D, Newman-Tancredi A, Costes N, Zimmer L
ACNP poster W166, Wednesday 6 December 2017, Poster session 3, 5h30 PM

NLX-101 ameliorates responses to hypercapnia in a mouse model of Rett syndrome
Abdala Sheikh A, Charles I, Koolen L, Varney M, Newman-Tancredi A
BPS poster PB082, Tuesday 12 December 2017, Poster session 5 PM

23 November 2017 - Neurolixis showcased online by "LaBiotech"

Neurolixis was recently showcased as the 'Biotech Of The Week" by LaBiotech.eu, the online European biotech networking website. The LaBiotech.eu article drew attention to Neurolixis' CNS drug development programs: NLX-112 for treatment of dyskinesia in Parkinson's disease, a disorder principally found in elderly patients; and NLX-101 for treatment of respiratory dysfunction in Rett syndrome, a rare orphan disorder that manifests itself in young girls.

Read the LaBiotech.eu article here.